Premium
Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer
Author(s) -
Yasumatsu Ryuji,
Wakasaki Takahiro,
Hashimoto Kazuki,
Nakashima Koichiro,
Manako Tomomi,
Taura Masahiko,
Matsuo Mioko,
Nakagawa Takashi
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25737
Subject(s) - nivolumab , medicine , neutrophil to lymphocyte ratio , oncology , head and neck cancer , head and neck squamous cell carcinoma , metastatic melanoma , lymphocyte , cancer , gastroenterology , immunotherapy
Background Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil‐to‐lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. Patients and Methods Forty‐one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. Results The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow‐up period. Conclusion Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.